Cost-Effectiveness of Fidaxomicin for Clostridium difficile Treatment

被引：2
|
作者：
Simon, Matthew S. [1 ,2 ]
机构：
[1] Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA
[2] Weill Cornell Med Coll, Dept Publ Hlth, New York, NY 10065 USA
来源：
CLINICAL INFECTIOUS DISEASES | 2014年 / 58卷 / 04期
关键词：
VANCOMYCIN; INFECTION; CANCER;
D O I：
10.1093/cid/cit772
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in Japan
    Okumura, Hiroyuki
    Ueyama, Maki
    Shoji, Shingo
    English, Marci
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2020, 26 (06) : 611 - 618
  • [2] Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection
    Chen, Jiahe
    Gong, Cynthia L.
    Hitchcock, Matthew M.
    Holubar, Marisa
    Deresinski, Stanley
    Hay, Joel W.
    CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (10) : 1448 - 1454
  • [3] Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France
    Watt, Maureen
    Dinh, Aur Elien
    Le Monnier, Alban
    Tilleul, Patrick
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (07) : 678 - 686
  • [4] Cost-Effectiveness Analysis Evaluating Fidaxomicin versus Oral Vancomycin for the Treatment of Clostridium difficile Infection in the United States
    Stranges, Paul M.
    Hutton, David W.
    Collins, Curtis D.
    VALUE IN HEALTH, 2013, 16 (02) : 297 - 304
  • [5] Cost-Effectiveness of Competing Treatment Strategies for Clostridium difficile Infection: A Systematic Review
    Phuc Le
    Nghiem, Van T.
    Mullen, Patricia Dolan
    Deshpande, Abhishek
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2018, 39 (04) : 412 - 424
  • [6] Fidaxomicin for the Treatment of Clostridium difficile infections
    Whitman, Craig B.
    Czosnowski, Quinn A.
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (02) : 219 - 228
  • [7] The Use of Fidaxomicin for Treatment of Relapsed Clostridium difficile Infections in Patients with Cancer
    Esmaily-Fard, Amin
    Tverdek, Frank P.
    Crowther, David M.
    Ghantoji, Shashank S.
    Adachi, Javier A.
    Chemaly, Roy F.
    PHARMACOTHERAPY, 2014, 34 (11): : 1220 - 1225
  • [8] Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain
    Carlos Rubio-Terrés
    José María Aguado
    Benito Almirante
    Javier Cobo
    Santiago Grau
    Miguel Salavert
    Elena González Antona Sánchez
    Cristina López Gutiérrez
    Darío Rubio-Rodríguez
    European Journal of Clinical Microbiology & Infectious Diseases, 2019, 38 : 1105 - 1111
  • [9] A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany
    Watt, Maureen
    McCrea, Charles
    Johal, Sukhvinder
    Posnett, John
    Nazir, Jameel
    INFECTION, 2016, 44 (05) : 599 - 606
  • [10] A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany
    Maureen Watt
    Charles McCrea
    Sukhvinder Johal
    John Posnett
    Jameel Nazir
    Infection, 2016, 44 : 599 - 606
12345